FreeO2 SCA: Comparaison of 2 SpO2 Level Measured by Pulse Oxymetry in Complications of Acute Coronary Syndrome.

Sponsor
Laval University (Other)
Overall Status
Completed
CT.gov ID
NCT03122210
Collaborator
(none)
60
3
87.2

Study Details

Study Description

Brief Summary

During acute coronary syndrome, the American College of Cardiology and the American Heart Association recommend oxygen delivery to patients with less than 90% oxygen saturation. Oxygen therapy in these patients for a duration of at least 6 hours, but also stipulates that it is reasonable to administer oxygen to all acute coronary syndrome patients during the first six hours following the presentation. Hyperoxia also has well-established risks.

Our research hypotheses are:

(I) that current practices tend to use high oxygen flows resulting in high SpO2 levels during acute coronary syndrome.

(II) there is a high rate of desaturation in patients with acute coronary syndrome and an automatic adaptation of oxygen flows may reduce this frequency.

(III) that excessive oxygenation targets have no advantage. Our hypothesis is that maintaining a SpO2 of 90 to 94% is at least equivalent when compared to higher saturation objectives (SpO2 of 94 to 100%) with regard to the occurrence of complications in the patient in acute coronary syndrome . We will use two SpO2 targets with the FreeO2 system, 92 and 97%.

Condition or Disease Intervention/Treatment Phase
  • Device: Automated oxygen administration
N/A

Detailed Description

Hypoxemia is a common problem encountered during acute coronary syndrome. During acute coronary syndrome, the American College of Cardiology and the American Heart Association recommend oxygen delivery to patients with less than 90% oxygen saturation. Oxygen therapy in these patients for a duration of at least 6 hours , but also stipulates that it is reasonable to administer oxygen to all acute coronary syndrome patients during the first six hours Following the presentation. However, the studies underlying these guidelines are few and far between, most of them having been done more than forty years ago.

Hyperoxia also has well-established risks.

Our research hypotheses are:

(I) that current practices tend to use high oxygen flows resulting in high SpO2 levels during acute coronary syndrome.

(II) there is a high rate of desaturation in patients with acute coronary syndrome and an automatic adaptation of oxygen flows may reduce this frequency. This will be our primary endpoint and will be tested with the use of the automated oxygen delivery system.

(III) that excessive oxygenation targets have no advantage. Our hypothesis is that maintaining a SpO2 of 90 to 94% is at least equivalent when compared to higher saturation objectives (SpO2 of 94 to 100%) with regard to the occurrence of complications in the patient in acute coronary syndrome . We will use two SpO2 targets with the FreeO2 system, 92 and 97%.

Study Design

Study Type:
Interventional
Actual Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Comparaison of 2 SpO2 Level Measured by Pulse Oxymetry in Complications of Acute Coronary Syndrome.
Actual Study Start Date :
Jan 5, 2010
Actual Primary Completion Date :
Aug 8, 2013
Actual Study Completion Date :
Apr 13, 2017

Arms and Interventions

Arm Intervention/Treatment
Other: Control group

In this group, the nursing staff administed oxygen supply if necessary with the usual pratice in care unit for 24 hours after myocard infarction. In this group the SpO2 was recorded any time with FreeO2 device - recording mode.

Device: Automated oxygen administration
In the control group, usual oxygen administration and titration is planned
Other Names:
  • Usual oxygen administration
  • Other: FreeO2 with SpO2 target = 92%

    In this group oxygen flow was automatically adjusted with the FreeO2 device (automatic titration of oxygen flow) to achived SpO2 target set by clinicial for 24 hours after myocard infarction. In this group, the SpO2 target was set at 92%.

    Device: Automated oxygen administration
    In the control group, usual oxygen administration and titration is planned
    Other Names:
  • Usual oxygen administration
  • Other: FreeO2 with SpO2 target =97%

    In this group oxygen flow was automatically adjusted with the FreeO2 device (automatic titration of oxygen flow) to achived SpO2 target set by clinicial for 24 hours after myocard infarction. In this group, the SpO2 target was set at 97%.

    Device: Automated oxygen administration
    In the control group, usual oxygen administration and titration is planned
    Other Names:
  • Usual oxygen administration
  • Outcome Measures

    Primary Outcome Measures

    1. The frequency of significant desaturations (SpO2 <90% for at least 30 seconds) [24 hours]

    Secondary Outcome Measures

    1. Significant rhythm disorders, ischemic events [24 hours]

    2. The percentage of time spent in the target SpO2 area in the second and third groups, defined as SpO2 +/- 2% of the targeted SpO2 (range 90-94% for group 92% and range 95-99% for group 97%) [24 hours]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients should have a proven diagnosis of acute high risk coronary syndrome as defined by the American Heart Association:

    • myocardial infarction with or without ST segment elevation: Ischemic changes in the electrocardiogram and positive cardiac biomarkers.

    • or Unstable angina: Typical or atypical cardiac symptoms, Ischemic electrocardiographic changes, Normal cardiac biomarkers.

    Exclusion Criteria:
    • inclusion in another study refusing co-enrollment

    • chronic obstructive pulmonary disease with CO2 retention

    • sleep apnea-hypopnea syndrome with CPAP

    • traumatic brain injury

    • pregnancy

    • Age <18 years

    • Mechanical invasive or non-invasive ventilation

    • patient needing more than 5 lpm of oxygen to have SpO2 > 95%

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Laval University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    François Lellouche, Principal investigator, Laval University
    ClinicalTrials.gov Identifier:
    NCT03122210
    Other Study ID Numbers:
    • 20502
    First Posted:
    Apr 20, 2017
    Last Update Posted:
    Dec 20, 2017
    Last Verified:
    Dec 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 20, 2017